A hybrid nanoadjuvant cascading activation of the cGAS-STING-IFN-Ⅰ pathway to enhance radio-immunotherapy
Source abstract
Abstract
The cGAS-STING signaling pathway is crucial for radiotherapy (RT)-induced immune modulation. However, under hypoxic conditions, reduced DNA damage and enhanced DNA damage repair (DDR) lead to lower cytosolic double-stranded DNA (dsDNA) levels, making standard RT doses inadequate for sustained cGAS-STING activation, resulting in transient immune responses. In this study, we developed the As-Mn@MnO2@Alb nanosystem as a potent radiosensitizer and cGAS-STING pathway amplifier. Arsenic trioxide (ATO)-mediated radiosensitization suppresses DDR, enhances immunogenic cell death, and increases tumor-associated antigens and cytosolic dsDNA levels. Concurrently, degradable MnO2 releases Mn2+ in tumors, boosting cGAS recognition and sensitivity, while generating oxygen to alleviate hypoxia and improve RT efficacy. The synchronized delivery of Mn2+ and accumulated cytosolic dsDNA amplifies cGAS-STING activation, promoting dendritic cell (DC) maturation, enhancing CD8+ T cell infiltration, reducing immunosuppressive Treg infiltration, and significantly inhibiting both irradiated local tumors and non-irradiated distal CRC tumors while inducing robust immune memory effects, all with no notable toxicity. This study demonstrates that effective RT sensitization, coupled with synchronized STING activation, represents a robust strategy to overcome radio-immunotherapy resistance in colorectal cancer.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: interferon and immune responses · Nanoplatforms for cancer theranostics · Cancer Immunotherapy and Biomarkers
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (81)
Show source-provided references
1. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2. Rectal cancer, version 2.2022, NCCN clinical practice guidelines in oncology10.6004/jnccn.2022.0051 ↗
3. The cGAS‒STING pathway in cancer immunity: mechanisms, challenges, and therapeutic implications10.1186/s13045-025-01691-5 ↗
4. The balance of STING signaling orchestrates immunity in cancer10.1038/s41590-024-01872-3 ↗
5. Regulation of cGAS–STING signalling and its diversity of cellular outcomes
6. The cGAS–cGAMP–STING pathway connects DNA damage to inflammation, senescence, and cancer10.1084/jem.20180139 ↗
7. Old dogs, new trick: classic cancer therapies activate cGAS10.1038/s41422-020-0346-1 ↗
8. The paradoxical role of radiation‐induced cGAS–STING signalling network in tumour immunity10.1111/imm.13592 ↗
9. TRIM21 inhibits irradiation-induced mitochondrial DNA release and impairs antitumour immunity in nasopharyngeal carcinoma tumour models10.1038/s41467-023-36523-y ↗
10. Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions10.1158/1078-0432.CCR-14-2824 ↗
11. Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy
12. Intratumoral radiation dose heterogeneity augments antitumor immunity in mice and primes responses to checkpoint blockade10.1126/scitranslmed.adk0642 ↗
13. Inflammatory microenvironment remodelling by tumour cells after radiotherapy10.1038/s41568-020-0246-1 ↗
14. Systemic immunity in cancer10.1038/s41568-021-00347-z ↗
15. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence10.1038/nrc3958 ↗
16. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer10.1038/s41392-020-0150-x ↗
17. Extrinsic phagocyte-dependent STING signaling dictates the immunogenicity of dying cells10.1016/j.ccell.2018.03.027 ↗
18. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity10.1038/ncomms15618 ↗
19. Enhancing radiotherapy-induced anti-tumor immunity via nanoparticle-mediated STING agonist synergy10.1186/s12943-025-02366-y ↗
20. An orally available non-nucleotide STING agonist with antitumor activity10.1126/science.aba6098 ↗
21. Immunotherapy with a sting10.1126/science.abc6622 ↗
22. Salvage chemotherapy regimens with arsenic trioxide for relapsed or refractory neuroblastoma: a promising approach10.1186/s12885-024-12884-5 ↗
23. Excellent early outcomes of combined chemotherapy with arsenic trioxide for stage 4/M neuroblastoma in children: a multicenter nonrandomized controlled trial10.3727/096504021X16184815905096 ↗
24. Improved outcomes with induction chemotherapy combined with arsenic trioxide in stage 4 neuroblastoma: a case series10.1177/15330338211041454 ↗
25. Assessment of arsenic trioxide and all-trans retinoic acid for the treatment of pediatric acute promyelocytic leukemia: a report from the children's oncology group AAML1331 trial10.1001/jamaoncol.2021.5206 ↗
26. Randomized clinical control study of locoregional therapy combined with arsenic trioxide for the treatment of hepatocellular carcinoma10.1002/cncr.29456 ↗
27. Arsenic trioxide prevents radiation-enhanced tumor invasiveness and inhibits matrix metalloproteinase-9 through downregulation of nuclear factor κB10.1038/sj.onc.1208192 ↗
28. Arsenic trioxide enhances the therapeutic efficacy of radiation treatment of oral squamous carcinoma while protecting bone10.1158/1535-7163.MCT-08-0287 ↗
29. Radiosensitivity enhancement by arsenic trioxide in conjunction with hyperthermia in the EC-1 esophageal carcinoma cell line10.7314/APJCP.2012.13.4.1693 ↗
30. Combination treatment with arsenic trioxide and irradiation enhances autophagic effects in U118-MG cells through increased mitotic arrest and regulation of PI3K/akt and ERK1/2 signaling pathways10.4161/auto.5.4.7759 ↗
31. Optimization of combination therapy of arsenic trioxide and fractionated radiotherapy for malignant glioma10.1016/j.ijrobp.2005.12.015 ↗
32. Molecular mechanisms of arsenic-induced disruption of DNA repair10.1021/acs.chemrestox.9b00464 ↗
33. Arsenic affects homologous recombination and single‐strand annealing but not end‐joining pathways during DNA double‐strand break repair10.1111/febs.16922 ↗
34. Nanodelivery of arsenic trioxide induces macrophage-governed cGAS-STING signaling to remodel immune microenvironment in hepatocellular carcinoma
35. Arsenic trioxide augments immunogenic cell death and induces cGAS-STING-IFN pathway activation in hepatocellular carcinoma10.1038/s41419-024-06685-8 ↗
36. Metabolism, toxicity and anticancer activities of arsenic compounds10.18632/oncotarget.14733 ↗
37. Smart human‐serum‐albumin–As2O3 nanodrug with self‐amplified folate receptor‐targeting ability for chronic myeloid leukemia treatment10.1002/anie.201701366 ↗
38. Biodegradable hollow MnO2 decorated by carbon dots with cholesterol depletion capability for cascaded amplification of sono-immunotherapy10.1016/j.biomaterials.2025.123559 ↗
39. Maintaining manganese in tumor to activate cGAS-STING pathway evokes a robust abscopal anti-tumor effect10.1016/j.jconrel.2021.01.036 ↗
40. Manganese increases the sensitivity of the cGAS-STING pathway for double-stranded DNA and is required for the host defense against DNA viruses10.1016/j.immuni.2018.03.017 ↗
41. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy10.1038/s41422-020-00395-4 ↗
42. Biomineralized MnO2 nanoplatforms mediated delivery of immune checkpoint inhibitors with STING pathway activation to potentiate cancer radio-immunotherapy10.1021/acsnano.2c10352 ↗
43. A hybrid nanoadjuvant simultaneously depresses PD‐L1/TGF‐β1 and activates cGAS‐STING pathway to overcome radio‐immunotherapy resistance10.1002/adma.202304328 ↗
44. An immunocompetent hafnium oxide-based STING nanoagonist for cancer radio-immunotherapy10.1021/acsnano.3c09293 ↗
45. Dual‐heterojunctions with reversibly photoactivated structure shift alternately decode photocatalytic H2 burst and Cascade catalytic ROS birth to repress cancer
46. Self-activated arsenic manganite nanohybrids for visible and synergistic thermo/immuno-arsenotherapy10.1016/j.jconrel.2022.08.054 ↗
47. Arginine‐loaded nano‐calcium‐phosphate‐stabilized lipiodol pickering emulsions potentiates transarterial embolization‐immunotherapy10.4028/b-XDTcg5 ↗
48. Arsenic trioxide augments immunogenic cell death and induces cGAS-STING-IFN pathway activation in hepatocellular carcinoma10.1038/s41419-024-06685-8 ↗
49. Priming anti-tumor immunity by radiotherapy: dying tumor cell-derived DAMPs trigger endothelial cell activation and recruitment of myeloid cells10.1080/2162402X.2018.1523097 ↗
50. Immunological impact of cell death signaling driven by radiation on the tumor microenvironment10.1038/s41590-019-0561-4 ↗
51. Detection of immunogenic cell death and its relevance for cancer therapy10.1038/s41419-020-03221-2 ↗
52. Targeting innate immune pathways for cancer immunotherapy10.1016/j.immuni.2023.07.018 ↗
53. How chemokines organize the tumour microenvironment10.1038/s41568-023-00635-w ↗
54. Dendritic cells and cancer immunity10.1016/j.it.2016.09.006 ↗
55. Serum protein-based nanoparticles for cancer diagnosis and treatment10.1016/j.jconrel.2020.10.030 ↗
56. Dual-synergistic nanomodulator alleviates exosomal PD-L1 expression enabling exhausted cytotoxic T lymphocytes rejuvenation for potentiated iRFA-treated hepatocellular carcinoma immunotherapy10.1021/acsnano.4c11257 ↗
57. Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma10.1200/JCO.20.00290 ↗
58. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non–small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial10.1001/jamaoncol.2019.1478 ↗
59. PAI-1-driven SFRP2high cancer-associated fibroblasts hijack the abscopal effect of radioimmunotherapy10.1016/j.ccell.2025.02.024 ↗
60. Radiotherapy enhances metastasis through immune suppression by inducing PD-L1 and MDSC in distal sites10.1158/1078-0432.CCR-23-3206 ↗
61. Multifunctional nanoparticle potentiates the in situ vaccination effect of radiation therapy and enhances response to immune checkpoint blockade10.1038/s41467-022-32645-x ↗
62. STING: a master regulator in the cancer-immunity cycle10.1186/s12943-019-1087-y ↗
63. A stimuli-responsive cuproptosis switch boosts persistent immunotherapy for tumor eradication
64. Biomineralized engineered bacterial outer membrane vesicles as cGAS-STING nanoagonists synergize with lactate metabolism modulation to potentiate immunotherapy10.1021/jacs.5c05148 ↗
65. Demystifying the cGAS-STING pathway: precision regulation in the tumor immune microenvironment10.1186/s12943-025-02380-0 ↗
66. Specific activation of cGAS-STING pathway by nanotherapeutics-mediated ferroptosis evoked endogenous signaling for boosting systemic tumor immunotherapy10.1016/j.scib.2023.02.027 ↗
67. Zinc cyclic di-AMP nanoparticles target and suppress tumours via endothelial STING activation and tumour-associated macrophage reinvigoration10.1038/s41565-022-01225-x ↗
68. Engineering radiosensitizer‐based metal‐phenolic networks potentiate STING pathway activation for advanced radiotherapy10.1002/adma.202105783 ↗
69. Bi2–x mn x O3 nanospheres engaged radiotherapy with amplifying DNA damage10.1021/acsami.3c06838 ↗
70. Ultra-efficient radio-immunotherapy for reprogramming the hypoxic and immunosuppressive tumor microenvironment with durable innate immune memory10.1016/j.biomaterials.2023.122303 ↗
71. Effective delivery of STING agonist using exosomes suppresses tumor growth and enhances antitumor immunity10.1016/j.jbc.2021.100523 ↗
72. Disrupting intracellular homeostasis by copper‐based nanoinducer with multiple enzyme‐mimicking activities to induce disulfidptosis‐enhanced pyroptosis for tumor immunotherapy
73. Near-infrared phosphorescent carbon dots for sonodynamic precision tumor therapy10.1038/s41467-022-33474-8 ↗
74. Single atom catalysts remodel tumor microenvironment for augmented sonodynamic immunotherapy10.1002/adma.202313670 ↗
75. Defect engineering of biodegradable sulfide nanocage sonozyme systems enables robust immunotherapy against metastatic cancers10.1002/adfm.202411064 ↗
76. Radiotherapy combined with immunotherapy: the dawn of cancer treatment10.1038/s41392-022-01102-y ↗
77. The abscopal effect: a sense of DNA damage is in the air10.1172/JCI148274 ↗
78. Using immunotherapy to boost the abscopal effect10.1038/nrc.2018.6 ↗
79. Radiation-induced amphiregulin drives tumour metastasis
80. Multi‐hierarchical fe single atom nanozymes with axially‐coordinated O‐fe‐N4 active centers reshape macrophage epigenetics against immunosuppression
81. Macrophage-inherited exosome excise tumor immunosuppression to expedite immune-activated ferroptosis10.1136/jitc-2022-006516 ↗